Vanguard Group Inc Cyteir Therapeutics, Inc. Transaction History

Vanguard Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.84 - $3.13 $132,375 - $145,892	46,611 Added 7.27%	687,391 $2.09 Million
Q3 2023 Nov 14, 2023	BUY	$2.71 - $2.84 $151,751 - $159,031	55,997 Added 9.58%	640,780 $1.82 Million
Q4 2022 Feb 10, 2023	BUY	$1.18 - $1.76 $343 - $512	291 Added 0.05%	584,783 $964,000
Q3 2022 Nov 14, 2022	SELL	$1.99 - $4.05 $53,940 - $109,779	-27,106 Reduced 4.43%	584,492 $1.12 Million
Q2 2022 Aug 12, 2022	BUY	$1.62 - $4.4 $367,164 - $997,238	226,645 Added 58.88%	611,598 $1.83 Million
Q1 2022 May 13, 2022	BUY	$3.39 - $10.51 $141,430 - $438,477	41,720 Added 12.16%	384,953 $1.45 Million
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $19,483 - $38,074	1,982 Added 0.58%	343,233 $3.9 Million
Q3 2021 Nov 12, 2021	BUY	$14.57 - $21.86 $3.95 Million - $5.93 Million	271,251 Added 387.5%	341,251 $5.99 Million
Q2 2021 Aug 13, 2021	BUY	$16.8 - $21.4 $1.18 Million - $1.5 Million	70,000 New	70,000 $1.5 Million

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.